AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $212.60, giving the company a market capitalization of 378.18B. It carries a P/E multiple of 161.50 and pays a dividend yield of 3.1%.
As of 2026-01-21, AbbVie(ABBV) stock has fluctuated between $209.96 and $214.24. The current price stands at $212.60, placing the stock +1.3% above today's low and -0.8% off the high.
The AbbVie(ABBV)'s current trading volume is 8.25M, compared to an average daily volume of 7.92M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
ABBV News
AbbVie (NYSE:ABBV) reported positive Phase 3 EPCORE DLBCL-1 data for epcoritamab in relapsed or refractory diffuse large B-cell lymphoma, highlighting improved...
Berenberg raised the firm’s price target on AbbVie (ABBV) to $275 from $270 and keeps a Buy rating on the shares. The firm upped its forecasts for AbbVie’s Skyr...
Key Points Eli Lilly has outstanding growth prospects thanks to its leadership in its core therapeutic area. AbbVie's immunosuppressant portfolio helps it to...
Analyst ratings
63%
of 32 ratingsMore ABBV News
These stocks sport dividend yields ranging from 2.9% to 5.5%. The power of investing in dividend-paying stocks is often underappreciated. Many people assume di...
Genmab (GMAB) on Friday announced that its bispecific antibody epcoritamab, marketed as Epkinly in partnership with AbbVie (ABBV), extended patient survival wit...
Claim 70% Off TipRanks Premium Genmab ( (GMAB) ) has shared an announcement. On January 16, 2026, Genmab reported topline Phase 3 results from its global EPCO...
Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for...
In recent days, AbbVie said it reached a voluntary three-year agreement with the Trump administration to cut prices on select medicines offered through Medicaid...
The latest trading session saw AbbVie (ABBV) ending at $193.45, denoting a -1.16% adjustment from its last day's close. This move lagged the S&P 500's daily gai...
Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for...